文献速递免疫规划

肺炎链球菌延伸因子Tu免疫可增强不依赖血清型的保护

Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection.
PubMed 文献 · Vaccine · 2018-11-13

本研究探讨肺炎链球菌延伸因子Tu(EF-Tu)作为不依赖血清型疫苗候选抗原的可能性。Western blotting和流式细胞术显示EF-Tu在所有受试菌株表面和胞内普遍表达;小鼠免疫重组EF-Tu后诱导炎性细胞因子、IgG1和IgG2a抗体及脾细胞CD4+ T细胞比例升高,抗EF-Tu血清增强巨噬细胞吞噬活性,且免疫小鼠对血清型2和15A致死攻击获得显著非特异性保护。

要点

  • EF-Tu在所有受试肺炎链球菌菌株表面和胞内普遍表达。
  • 重组EF-Tu免疫小鼠诱导炎性细胞因子、IgG1/IgG2a抗体及CD4+ T细胞比例升高。
  • 免疫小鼠对血清型2和15A致死攻击获得显著非特异性保护。

核心结论

  • 肺炎链球菌EF-Tu可作为不依赖血清型疫苗的候选抗原。

研究设计与样本

  • 实验研究:分析EF-Tu在多种肺炎链球菌菌株的表达,并评估重组EF-Tu免疫小鼠的免疫应答和保护效果。

主要发现

  • Western blotting和流式细胞术显示EF-Tu在所有受试菌株表面和胞内普遍表达。
  • 重组EF-Tu免疫小鼠诱导炎性细胞因子、IgG1和IgG2a抗体产生,并增加脾细胞中CD4+ T细胞比例。
  • 抗EF-Tu血清增强小鼠腹腔巨噬细胞对肺炎链球菌的吞噬活性,不依赖血清型。
  • 重组EF-Tu免疫小鼠对血清型2和15A致死攻击获得显著非特异性保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccination is an effective strategy to prevent pneumococcal diseases. Currently, licensed vaccines include the pneumococcal polysaccharide vaccine (PPSV) and the pneumococcal conjugate vaccine (PCV), which target some of the most common of the 94 serotypes of S. pneumoniae based on their capsular composition. However, it has been reported that PPSV is not effective in children aged less than 2 years old and PCV induces serotype replacement, which means that the pneumococcal population has changed following widespread introduction of these vaccines, and the non-vaccine serotypes have increased in being the cause of invasive pneumococcal disease. Therefore, it is important that there is development of novel pneumococcal vaccines to either replace or complement current polysaccharide-based vaccines. Our previous study suggested that S. pneumoniae releases elongation factor Tu (EF-Tu) through autolysis followed by the induction of proinflammatory cytokines in macrophages via toll-like receptor 4, that may contribute to the development of pneumococcal diseases. In this study, we investigated the expression of EF-Tu in various S. pneumoniae strains and whether EF-Tu could be an antigen candidate for serotype-independent vaccine against pneumococcal infection. Western blotting and flow cytometry analysis revealed that EF-Tu is a common factor expressed on the surface of all pneumococcal strains tested, as well as intracellularly. In addition, we demonstrate that immunization with recombinant (r) EF-Tu induced the production of inflammatory cytokines and the IgG1 and IgG2a antibodies in mice, and increased the CD4+ T-cells proportion in splenocytes. We also reveal that anti-EF-Tu serum increased the phagocytic activity of mouse peritoneal macrophages against S. pneumoniae infection, independent of their serotypes. Finally, our results indicate that mice immunized with rEF-Tu were significantly and non-specifically protected against lethal challenges with S. pneumoniae serotypes (2 and 15A). Therefore, pneumococcal EF-Tu could be an antigen candidate for the serotype-independent vaccine against pneumococcal infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nagai K, Domon H, Maekawa T, et al. Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection. Vaccine. 2018. PMID: 30442480. doi:10.1016/j.vaccine.2018.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。